Recursion Pharmaceuticals (NASDAQ:RXRX) Stock: Insider Robert Hershberg Sells 25,000 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Robert Hershberg sold 25,000 shares of the stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $5.00, for a total value of $125,000.00. Following the completion of the sale, the director owned 162,156 shares of the company’s stock, valued at approximately $810,780. This trade represents a 13.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock opened at $3.95 on Friday. The stock’s 50 day moving average price is $3.54 and its 200 day moving average price is $3.38. The firm has a market capitalization of $2.11 billion, a PE ratio of -3.80 and a beta of 1.04. Recursion Pharmaceuticals, Inc. has a one year low of $2.77 and a one year high of $7.18. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.03.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The firm had revenue of $7.67 million for the quarter, compared to analysts’ expectations of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same period last year, the firm earned ($0.41) EPS. As a group, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -0.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. MCF Advisors LLC bought a new position in shares of Recursion Pharmaceuticals in the 2nd quarter worth about $27,000. Fund Advisors of America Inc FL bought a new stake in shares of Recursion Pharmaceuticals during the 2nd quarter valued at about $45,000. Integral Investment Advisors Inc. acquired a new stake in Recursion Pharmaceuticals during the first quarter worth about $39,000. MQS Management LLC acquired a new stake in Recursion Pharmaceuticals during the first quarter worth about $41,000. Finally, Sequoia Financial Advisors LLC lifted its holdings in Recursion Pharmaceuticals by 51.5% in the first quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock worth $47,000 after acquiring an additional 5,156 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Wall Street Zen upgraded Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th. Finally, Morgan Stanley set a $5.30 price objective on Recursion Pharmaceuticals in a report on Monday, August 17th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $8.06.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.